Literature DB >> 10149134

Contrast media for angiography: physicochemical properties, pharmacokinetics and biocompatibility.

R Eloy1, C Corot, J Belleville.   

Abstract

Contrast agents are used as diagnostic molecules for the visualization of the vascular system. Despite their rapid pharmacokinetic distribution, and their excretion within a few minutes, their injection is associated with clinical symptoms of relative bioincompatibility. Allergoid reactions and disturbances of the hemostatic system represent the main fields of biological investigations. Due to the extent of clinical and experimental works the ubiquitous interactions between these molecules and cellular and/or protein systems have emerged. The development of a new family of low osmolality ionic or non-ionic contrast molecules had decreased the incidence of minor reactions, but did not modify the frequency of severe accidents and even led to the emergence of new iatrogenic syndromes. Despite extensive laboratory investigations there are still no predictive criteria nor any specific therapeutic prevention of these allergoid reactions. The suggested future line of investigation concerns the physicochemical interaction of CM and targeted biological systems which may allow the analysis and predictivity of these interactions at the molecular level.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 10149134     DOI: 10.1016/0267-6605(91)90045-h

Source DB:  PubMed          Journal:  Clin Mater        ISSN: 0267-6605


  10 in total

1.  Roles of intracellular Ca2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media.

Authors:  Mami Saito; Yoshinori Itoh; Takahisa Yano; Toshiaki Sendo; Takeshi Goromaru; Naoko Sakai; Ryozo Oishi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-03-06       Impact factor: 3.000

Review 2.  Effects of iodinated contrast media on blood and endothelium.

Authors:  Peter Aspelin; Fulvio Stacul; Henrik S Thomsen; Sameh K Morcos; Aart J van der Molen
Journal:  Eur Radiol       Date:  2006-01-05       Impact factor: 5.315

3.  Similar inhibition of platelet adhesion, P-selectin expression and plasma coagulation by ioversol, iodixanol and ioxaglate.

Authors:  J P Fägerstam; A K Ostberg; A C Eriksson; S-G Fransson; P A Whiss
Journal:  Br J Radiol       Date:  2009-06-22       Impact factor: 3.039

4.  Study of the complex between the contrast agent Iobitridol (Xenetix) and Elastase (PPE): a model for hydrophobic site protection in drug-protein interactions.

Authors:  T Prangé; A Neuman; C Corot; D Meyer
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

5.  Safety of iobitridol in the general population and at-risk patients.

Authors:  Thomas J Vogl; Elmar Honold; Michael Wolf; H Mohajeri; R Hammerstingl
Journal:  Eur Radiol       Date:  2006-01-21       Impact factor: 5.315

Review 6.  Comparative tolerability of contrast media used for coronary interventions.

Authors:  Enrique Esplugas; Angel Cequier; Joan A Gomez-Hospital; Bruno García Del Blanco; Francisco Jara
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  An overview of the clinical pharmacokinetics of x-ray contrast media.

Authors:  M Bourin; P Jolliet; F Ballereau
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

8.  Results of the safety and efficacy of iobitridol in more than 61,000 patients.

Authors:  J Petersein; C R Peters; M Wolf; B Hamm
Journal:  Eur Radiol       Date:  2002-10-08       Impact factor: 5.315

9.  Effect of the radiographic contrast material iopamidol on hemostasis: an observational study in thirty cardiac patients.

Authors:  Yurdanur Kilinç; Ilgen Saşmaz; Abdi Bozkurt; Bülent Antmen; Esmeray Acartürk
Journal:  Curr Ther Res Clin Exp       Date:  2003-07

Review 10.  Contrast media viscosity versus osmolality in kidney injury: lessons from animal studies.

Authors:  Erdmann Seeliger; Diana C Lenhard; Pontus B Persson
Journal:  Biomed Res Int       Date:  2014-02-23       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.